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Validation of non-invasive methods of liver fat quantification requires a reference standard.
However, using standard histopathology assessment of liver biopsies is problematical
because of poor repeatability. We aimed to assess a stereological method of measuring vol-
umetric liver fat fraction (VLFF) in liver biopsies and to use the method to validate a mag-
netic resonance imaging method for measurement of VLFF.
Methods
VLFFs were measured in 59 subjects (1) by three independent analysts using a stereologi-
cal point counting technique combined with the Delesse principle on liver biopsy histological
sections and (2) by three independent analysts using the HepaFat-Scan1 technique on
magnetic resonance images of the liver. Bland Altman statistics and intraclass correlation
(IC) were used to assess the repeatability of each method and the bias between the meth-
ods of liver fat fraction measurement.
Results
Inter-analyst repeatability coefficients for the stereology and HepaFat-Scan1methods
were 8.2 (95% CI 7.7–8.8)% and 2.4 (95% CI 2.2–2.5)% VLFF respectively. IC coefficients
were 0.86 (95% CI 0.69–0.93) and 0.990 (95% CI 0.985–0.994) respectively. Small biases
(3.4%) were observable between two pairs of analysts using stereology while no
PLOSONE | DOI:10.1371/journal.pone.0160789 August 8, 2016 1 / 18
a11111
OPEN ACCESS
Citation: St. Pierre TG, House MJ, Bangma SJ,
Pang W, Bathgate A, Gan EK, et al. (2016)
Stereological Analysis of Liver Biopsy Histology
Sections as a Reference Standard for Validating Non-
Invasive Liver Fat Fraction Measurements by MRI.
PLoS ONE 11(8): e0160789. doi:10.1371/journal.
pone.0160789
Editor: Bing Xu, Brandeis University, UNITED
STATES
Received: April 21, 2016
Accepted: July 25, 2016
Published: August 8, 2016
Copyright: © 2016 St. Pierre et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: Resonance Health Ltd directly funded the
cost of the MRI scans and the services of one
pathologist who is not an author. Resonance Health
Ltd provided support in the form of salaries for
authors [SB, WP, AB], but did not have any additional
role in the study design, analysis, or decision to
publish. [WP] was involved in data collection
(stereology and Hepafat-Scan1) and [SB, WP, AB]
contributed to the preparation of the manuscript. The
significant biases were observable between any of the three pairs of analysts using Hepa-
Fat-Scan1. A bias of 1.4±0.5% VLFF was observed between the HepaFat-Scan1method
and the stereological method.
Conclusions
Repeatability of the stereological method is superior to the previously reported performance
of assessment of hepatic steatosis by histopathologists and is a suitable reference standard
for validating non-invasive methods of measurement of VLFF.
Introduction
Fatty liver, particularly non-alcoholic fatty liver disease (NAFLD) is a common aberrant liver
condition encountered in many general populations. The prevalence of NAFLD is considered
to be increasing [1–4] and there is growing literature describing associations of NAFLD with
cirrhosis [5], metabolic disorders, notably obesity [6], diabetes [7] and atherosclerotic cardio-
vascular disease [8, 9]. Consequently, there is a need for accurate quantification of liver fat in
research settings. There is also likely to be increasing need in future clinical practice where
accurate fat quantification could be used to improve liver resection strategies and transplant
screening [10]. Such measurements could also become more relevant for diagnosing and moni-
toring the treatment of conditions like NAFLD and NASH in the advent of pharmaceutical
treatments becoming available. An increasing number of published studies describe the corre-
lation between measures of hepatic steatosis using magnetic resonance imaging (MRI) or mag-
netic resonance spectroscopy (MRS) methods and measures of hepatic steatosis assessed in
liver biopsy specimens [11–31]. The interest in the correlation between the magnetic resonance
(MR) measure and the histological measure stems from the fact that the vast majority of the
gastroenterological and hepatological literature regarding relationships between degree of liver
steatosis and progression of disease and patient outcomes use histological studies of liver biop-
sies to deduce the degree of steatosis. Hence the measurement of steatosis in histological sec-
tions of biopsies has been considered the reference standard measurement. Knowledge of how
MRmeasures of liver steatosis relate to histological measures of steatosis is a requirement for
interpreting the results fromMR in the context of observations made from the vast literature of
clinical studies using biopsy.
Moderate to strong correlations between MR measures and measures of steatosis in biopsy
histological sections are found in the aforementioned studies. However, a strong correlation
coefficient between a MR measurement of steatosis and measures of steatosis in biopsies is, in
itself, not sufficient to enable MR results to be translated to biopsy results. The regression equa-
tion relating the MR measure to the biopsy measure is also required but is usually not reported.
Such an equation enables the MR method to be calibrated against the biopsy method. In princi-
ple, once calibrated, the MR method can then be validated on other MR scanners and in differ-
ent populations of patients by comparison with the reference standard, namely the
measurement of steatosis in biopsies of those patients. A lack of significant bias between the
MR method and the reference standard method would indicate validation of the calibration of
the MR method in the new population.
Magnetic resonance methods tend to report the proton density fat fraction or the fraction of
proton signal emanating from fat molecules while biopsy assessments often report a histopa-
thologist’s semi-quantitative assessment of steatosis in terms of the fraction of hepatocytes
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involved with fatty vesicles. This difference in the nature of the two measurements leads to sev-
eral problems for calibration and validation of the MR method against biopsy.
Firstly, histopathologists’ assessments of steatosis in liver biopsies have very poor repro-
ducibility making them an unreliable reference standard [32]. Even in the case of accurate
assessment by the histopathologist, MR reported and histology reported fat fractions will not
be equivalent. For example, if a histopathologist reports 100% of hepatocytes being involved
with steatosis, there will still be water protons present in the tissue and hence MR methods
will report a fraction of protons that is substantially lower than 100%. Secondly, for a given
fraction of hepatocytes involved with steatosis, the amount of fat per cell may vary between
individuals and between forms of disease. For example, the ratio of microvesicular to macro-
vesicular fat may vary between patients. In some studies investigators have attempted to ame-
liorate the problem of the semi-quantitative nature of histopathological assessment by
employing computer assisted morphometric methods to measure the fractional area of the
tissue in a biopsy specimen that is fat [14, 18, 19, 25, 26, 29]. The fractional area of the thin
tissue section that is represented by fatty vesicles is equivalent to the volumetric fraction of
fatty vesicles in the tissue (the Delesse Principle) [33]. However, computer assisted morpho-
metric methods rely on assumptions regarding the shape and size of fatty vesicles and also
rely on a subjective determination of image intensity thresholds [14, 19, 25, 26, 29]. As such,
computer assisted morphometric analysis methods of measuring the fraction of fat in the
liver are subject to a bias, the magnitude of the bias depending on the assumptions used.
Magnetic resonance methods of measuring the fraction of protons that are from fatty mole-
cules are also subject to bias. Different methods can yield different results for the same liver
tissue, the results depending on whether or not background noise is taken into account, and
the value of various MR data acquisition parameters used, such as flip angle and repetition
time [34–36].
As such, there is a need for a reliable reference standard against which non-invasive meth-
ods of measuring liver fat fraction can be evaluated that provides a quantitative link between
the MR method and observations made on liver biopsy sections. Given that clinical guidelines
related to the interpretation of the severity of hepatic steatosis (fatty liver) are based on hepatol-
ogists’ interpretations of liver biopsy specimens, there is a strong argument that reliable unbi-
ased quantitative assessment of the fraction of fat in liver biopsy specimens should be the basis
for an appropriate reference standard.
Stereological analysis of histological sections has been used for several decades to obtain
estimates of the volume fraction of phases or materials in both biological tissues and inor-
ganic media with minimum bias [33, 37–40]. In the current study, stereological analysis of
liver biopsy histological sections was used to obtain volumetric liver fat fractions (here
defined as the volume fraction of the liver that comprises fatty vesicles) in order to assess the
bias in an MRI method for measuring volumetric liver fat fraction. The MRI method, Hepa-
Fat-Scan1, received FDA clearance for marketing in December 2013 and CE Mark in July




Written informed consent was obtained from each subject and the study protocol conformed
to the ethical guidelines of the 1975 Declaration of Helsinki. This study was approved by the
Fremantle Hospital Human Research Ethics Committee and the Sir Charles Gairdner Hospital
Human Research Ethics Committee.
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Subjects
65 patients were enrolled in the study. The patients were recruited from the hepatology outpa-
tient clinics at Fremantle and Sir Charles Gairdner Hospitals, Western Australia. The patient
inclusion criteria were: age between 18 and 75 years, requirement of a liver biopsy for routine
clinical management, and written informed consent. Exclusion criteria were: contraindications
for MRI, pregnancy or lactation. One patient was excluded due to fluctuations in weight and
alcohol consumption during the period between liver biopsy and MRI. An additional five
patients were excluded for incorrect MRI data acquisition or unavailability of histological slides
for analysis leaving 59 participants. The median interval between biopsy and MRI was 57 days.
Summary data for the subjects are shown in Table 1. The diversity of etiologies included in the
study was to ensure that volumetric liver fat fractions across the entire clinically encountered
range were represented in the study.
Measurement of Volumetric Fat Fraction in Liver Histological Sections
The patients underwent percutaneous liver biopsy with ultrasound guidance as part of their rou-
tine clinical management. Biopsy sections were prepared and stained with Masson’s trichrome.
Histological sections of the biopsies were scanned in colour using an Aperio ScanScope XT
(Aperio Technologies, Inc., California, USA) automated slide scanner and ImageScope software.
The mean area of biopsy tissue in the histological sections was 14.4 (±SD 6.2) mm2.
Volumetric fat fraction was measured from the histological thin sections using the stereo-
logical grid-point counting method combined with the Delesse principle [33, 40]. The key rea-
sons for choosing this method are that such an approach (1) measures volumetric fat fraction
(which can be compared with the HepaFat-Scan1 MRI measurement) and (2) in principle is
unbiased with regard to the methodology [41, 42]. The stereological method of grid-point
counting to measure the fat content of liver biopsies has been used in previous studies [37–39,
43]. The method is based on systematic random sampling of the microscope digital image. The
Table 1. Study cohort clinical data.
Characteristics Patients Recruited Patients with MRI and Biopsy Histology Results
N 65 59
Gender (F/M) 31/34 29/30
Age (years), median (range) 56 (20–72) 56 (20–72)
BMI (kg/m2), mean ± st. dev. 29.00 ± 5.11 28.92 ± 5.17










Abbreviations: AIH, autoimmune hepatitis; ALD, alcoholic liver disease; BMI, body mass index; HBV-HCV, viral hepatitis B/C; LIC, liver iron concentration;
MRI, magnetic resonance imaging; NAFLD, non-alcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NORM, normal; PSC, primary sclerosing
cholangitis.
doi:10.1371/journal.pone.0160789.t001
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random component of the sampling is the random placement of a square grid over the image
while the systematic component is assessment of every grid intersection that falls on the tissue
section. Each intersection is examined by an analyst to determine whether or not it falls on a
fat vesicle (Fig 1). There are no assumptions about size, shape, or distribution of fat vesicles in
the sample. There is an assumption that if there is tissue shrinkage or expansion, that the holes
representing the fat vesicles shrink or expand to the same degree.
For each biopsy digital image, the mesh of the grid was adjusted so that approximately 200
intersections fell within the tissue boundaries. The number of 200 intersections was determined
as a compromise between precision of estimate and time required to complete an analysis as
follows. Navigation to, examination of, and recording of the result from an intersection
requires approximately 1 minute. The standard error on the estimate of area fraction, f, using
the stereological technique with n intersections is given as
p
[f(1-f)/n] [40]. Initial semi-quanti-
tative examination of the biopsy sections indicated that vesicle area fractions ranged from
approximately 1% to 40%. The choice of 200 intersections per biopsy results in standard errors
ranging from 0.7% for volumetric fat fractions of 1% at the low end of the range up to 3% for
volumetric fat fractions of 40% at the high end of the range with an overall analyst observation
time of approximately 3 hours per biopsy. With an average standard error on a measurement
of f of approximately 2% and 59 biopsies, 200 intersections per biopsy would result in a lower
Fig 1. Stereological analysis of biopsy sections. (a) Example histological section of a liver biopsy with
square grid randomly placed over image. The grid size was adjusted so that approximately 200 intersections
are located within the tissue boundary. Every intersection within the tissue boundary is visually examined to
determine whether or not it falls on a fat vesicle. The volumetric fat fraction for this example was determined
to be 18.6%. (b) High magnification image of four of the intersections in (a). The lower left grid intersection
was assessed to be within a fat vesicle while the other three intersections were assessed to be outside fat
vesicles. The distance between two neighbouring intersections is 250 microns or 504 pixels in this example.
Note that the grid lines are shown thicker here than in the analysis for clarity of display. During analysis the
grid lines are one pixel wide at the highest magnification.
doi:10.1371/journal.pone.0160789.g001
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limit of detection of bias of stereology against another method of approximately 0.02/p
59 = 0.3% volumetric liver fat fraction.
Each intersection was inspected and assigned to be either within a fat vesicle, outside of a fat
vesicle, or sitting on the boundary of a fat vesicle. After initial assignment of each intersection,
50% of the intersections initially assigned to boundaries were reassigned to being inside a vesi-
cle while the other 50% were reassigned to being outside a vesicle. The area fraction of the fat
vesicles was estimated by calculating the ratio of intersections assigned to being inside fat vesi-
cles to the total number of intersections within the tissue boundaries.
Each biopsy sample was analysed using the point counting stereology method by three inde-
pendent analysts.
Grading of Steatosis in Biopsy Sections by Hepatopathologists
Three experienced hepatopathologists (blinded to the patients’ identities, the MRI results, and
the stereology results) graded each biopsy sample from 0 to 3 according to the NASH Clinical
Research Network Scoring System [44]. Receiver operating characteristic curve (ROC curve)
analysis was used to identify thresholds of volumetric liver fat fraction by stereology and by
MRI that resulted in the highest sum of sensitivity and specificity for prediction of steatosis
grades>0,>1, and>2 for each hepatopathologist.
MRI Data Acquisition
All MRI measurements were made on Siemens 1.5 T Avanto scanners (Siemens Medical Sys-
tems, Erlangen, Germany) at Fremantle Hospital, St John of God Murdoch Hospital, and Hol-
lywood Private Hospital, Western Australia. The median time between biopsy and MRI was 57
days. Data were acquired as prescribed by the HepaFat-Scan1 methodology (Resonance
Health Ltd, Perth, Australia). Phased-array torso coils were centred over the liver of the sub-
jects. MRI data acquisition comprised an opposed-phase, in-phase, opposed-phase gradient
echo sequence (TEs 2.38, 4.76, 7.14 ms, TR 88 ms, 1 excitation, flip angle 70 degrees, bandwidth
500 Hz). Data from three axial slices, positioned through the widest part of the liver, were
acquired in a single breath-hold. The slice thickness was 4 mm and the matrix was 256 x 256
with a field of view 300 x 300 mm. Liver iron concentrations (LIC) were measured using a vali-
dated non-invasive MRI method (FerriScan1) [45, 46].
MR Image Processing
On each of the three MR image slices, a circular region of interest (ROI) about 580 mm2 was
delineated within the right lobe of the liver, avoiding large intrahepatic vessels and any obvious
motion-affected regions (Fig 2a). The image intensity was measured in the ROI and also in a
region of free space outside of the patient in order to measure background noise (Fig 2b). The
data from these measurements were then processed by the HepaFat-Scan1 software (Reso-
nance Health Analysis Services Pty Ltd, Claremont, WA, Australia) to generate a volumetric
liver fat fraction. Each image dataset was analysed by three independent analysts.
Statistical Analysis
Repeatability coefficients for each method of measurement of volumetric liver fat fraction were
calculated from the three measurements on each subject by three different analysts. Firstly the
within-subject standard deviation, sw, was calculated by taking the square root of the residual
mean square obtained from one-way analysis of variance, with the subject as the factor [47].
The repeatability coefficient for each method is given by 1.96(
p
2) sw or 2.77 sw. In the context
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of this study, two readings by two different analysts working on the same biopsy section or MR
image data will be within 2.77 sw of each other for 95% of subjects. The upper and lower 95%
confidence limits on the calculated repeatability coefficients were calculated following the
method of Bland and Altman [47]. The conformity of analysts using each technique was also
assessed by calculating the intraclass correlation coefficient (ICC). The method of Shrout and
Fleiss [48] was used to calculate the ICCs (type (2,1)) together with their 95% confidence inter-
vals. The ICC is an estimate of the proportion of the total variance of all subjects and all ana-
lysts that is due to the subjects alone, the remaining variance being due to other sources such as
inter-analyst and intra-analyst variability.
For the stereological measurement of volumetric liver fat fraction in biopsies, the MR mea-
surement of volumetric liver fat fraction by HepaFat-Scan1, and the assessment of percentage
fat by the hepatopathologists, the bias between the different pairs of analysts was assessed using
the method of Bland and Altman [47].
The degree of bias between measurements of volumetric liver fat fraction in the biopsy sec-
tions and measurements of volumetric liver fat fraction made by HepaFat-Scan was determined
using the methods of Bland and Altman [47]. The average measurement from three indepen-
dent analysts was used for both the biopsy measurement and the HepaFat-Scan measurement.
The 95% limits of agreement between the two methods of measuring volumetric liver fat frac-
tion were also assessed using the methods of Bland and Altman [47].
Results
Demographic and Clinical Data
Demographic and clinical data for the recruited patients are shown in Table 1. The distribution
of METAVIR fibrosis stages for the patients included in the study was F0 (19%), F1 (38%), F2
(22%), F3 (12%), F4 (9%). The distribution of steatosis grades according to the NASH CRN
grading system [44] as assessed by the average of the three percentage steatosis assessments by
the histopathologists was: grade 0 (47%), grade 1 (15%), grade 2 (17%), grade 3 (20%). Five
patients (9%) had liver iron concentration (LIC) levels above the upper 95% limit of normal
(1.8 mg Fe/g dry tissue) with the maximum LIC being 4.4 mg Fe/g dry tissue.
The volumetric liver fat fractions determined by stereological analysis of the biopsy sections
ranged from 0.7% to 32.6% while those measured by HepaFat-Scan1 ranged from 0.8% to
32.7%. Details of all data reported in this study are shown in S1 Table.
Fig 2. Magnetic resonance images of the liver. (a) A typical region of interest selected for analysis within
the liver magnetic resonance image. (b) A typical region of interest of free space selected within the MR
image for measurement of background noise.
doi:10.1371/journal.pone.0160789.g002
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Inter-Analyst Repeatability of Measurements of Fat Fraction
The repeatability coefficient (three analysts) of the grid point counting stereological method
for measurement of volumetric fat fractions in the biopsy sections was found to be 8.2 (95% CI
7.7–8.8) % volumetric fat fraction indicating that 95% of pairs of results from any pair of ana-
lysts were within 8.2% of each other. The repeatability coefficient (three analysts) of HepaFat-
Scan1 for measurement of volumetric fat fractions was found to be 2.4 (95% CI 2.2–2.5) % vol-
umetric fat fraction indicating that 95% of pairs of results from any pair of analysts were within
2.4% of each other. The repeatability coefficient (three hepatopathologists) for assessment of
percentage steatosis was found to be 38 (95% CI 35–40) % indicating that 95% of pairs of
results from any pair of hepatopathologists were within 38% of each other.
The ICC determined from the stereological analyses of the 59 biopsies by three analysts was
0.86 (95% CI 0.69–0.93). The ICC determined from the analyses of the 59 sets of MRI data by
three analysts using the HepaFat-Scan1 method was 0.990 (95% CI 0.985–0.994). The ICC
determined from the hepatopathologists assessments of percentage steatosis in the 59 biopsies
was 0.79 (95% CI 0.68–0.87).
Assessment of the bias between the three analysts using stereology to measure the volumet-
ric liver fat fraction in the biopsy sections indicated that there was no significant bias between
two of the analysts (Analysts S and Analyst M) but that there was significant bias between Ana-
lyst W and the other two analysts 2.9 ± 0.4% and 3.4 ± 0.5% (Fig 3)
Assessment of the bias between the three analysts using HepaFat-Scan1 to measure the vol-
umetric liver fat fraction indicated that there was no significant bias between any of the analysts
(Fig 4).
Measurement of the bias between the three hepatopathologists assessments of percentage
steatosis in the biopsy sections indicated that there was no significant bias between two of the
hepatopathologists (AC and PB) but that there was significant bias between hepatopathologist
BD and the other two hepatopathologists 10.7 ± 1.8% and 13.9 ± 2.7% (Fig 5).
Comparison of MRI and Histological Volumetric Fat Measurements
Fig 6a shows the volumetric liver fat fractions measured by MRI (mean of three observers) ver-
sus the volumetric liver fat fractions measured from the histological biopsy sections (mean of
three observers) for the 59 subjects. The solid line is the line of equivalence. A Bland Altman
plot of the difference between the two measurements plotted against the mean of the two mea-
surements of volumetric liver fat fraction is shown in Fig 6b. The mean difference of the volu-
metric fat fractions measured by the two techniques was found to be 1.4% ± SE 0.5% (solid line
in Fig 6b). The upper and lower 95% limits of agreement between the two techniques were
found to be 8.7% and -6.0% respectively (dashed lines in Fig 6). No significant difference was
found between the mean difference for the 5 subjects with elevated LIC and the mean differ-
ence for all other subjects. The subject with the highest LIC had the smallest bias relative to the
non-iron-loaded subjects. In order to assess any impact of fibrosis stage on the bias and preci-
sion observed between the MRI and stereology measurements of volumetric liver fat fraction,
VLFF differences were grouped into five categories corresponding to the METAVIR fibrosis
stages 0 to 4. One way ANOVA showed neither significant differences among the mean differ-
ences (p = 0.80) nor significant differences among the variances of differences (p = 0.18) for
each fibrosis stage.
Comparison of MRI and Stereology with Histopathology Grading
Table 2 shows the optimal cut points (thresholds) of volumetric liver fat fraction (as a per-
centage) measured by stereology and by HepaFat-Scan1 for discrimination of the different
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PLOS ONE | DOI:10.1371/journal.pone.0160789 August 8, 2016 8 / 18
grades of steatosis assessed by the three hepatopathologists. Table 2 also shows the areas
under the ROC curves and sensitivities and specificities of stereology and HepaFat-Scan1 for
predicting steatosis grades assessed by each of the three hepatopathologists using the stated
cut points.
Fig 3. Inter-analyst comparison of the stereology results.Comparisons of results of measurement of
volumetric liver fat fraction in 59 biopsy sections by three independent analysts (identified as S, M, andW)
using the stereology method. The left column shows plots of the results from one analyst against the results
from another. The solid line is the line of equivalence (not a line of best fit). The right columns shows Bland
Altman plots of the difference in results between two analysts plotted against the mean result from two
analysts. The horizontal solid line indicates the mean difference between the two analysts while the dashed
lines indicate the upper and lower 95% limits of agreement between the two analysts.
doi:10.1371/journal.pone.0160789.g003
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Discussion
Technological advances in medical imaging have led to the development of a number of differ-
ent non-invasive methods for quantifying hepatic steatosis [49–53]. Limitations of the use of
conventional histopathological assessment of biopsy data for validation of or comparison with
Fig 4. Inter-analyst comparison of the HepaFat-Scan1 MRI results. Comparisons of results of
measurement of volumetric liver fat fraction in 59 MRI datasets by three independent analysts (identified as
R, S, andW) using the HepaFat-Scan1method. The left column shows plots of the results from one analyst
against the results from another. The solid line is the line of equivalence (not a line of best fit). The right
columns shows Bland Altman plots of the difference in results between two analysts plotted against the mean
result from two analysts. The horizontal solid line indicates the mean difference between the two analysts
while the dashed lines indicate the upper and lower 95% limits of agreement between the two analysts.
doi:10.1371/journal.pone.0160789.g004
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these methods are the variability and sensitivity of assessment [32]. For example, in a study of
the assessment of steatosis in 46 biopsies by four expert pathologists from 4 prominent centers
in 3 countries across Europe and North America, quantification of hepatic steatosis was found
to be strongly observer-dependent, not reproducible, and did not correlate with the
Fig 5. Inter-analyst comparison of hepatopathologists results.Comparisons of results of assessment of
percentage steatosis in 59 biopsy sections by three independent hepatopathologists (identified as AC, BD,
and PB). The left column shows plots of the results from one hepatopathologist against the results from
another. The solid line is the line of equivalence (not a line of best fit). The right columns shows Bland Altman
plots of the difference in results between two hepatopathologists plotted against the mean result from two
hepatopathologists. The horizontal solid line indicates the mean difference between the two
hepatopathologists while the dashed lines indicate the upper and lower 95% limits of agreement between the
two hepatopathologists.
doi:10.1371/journal.pone.0160789.g005
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computerized estimation [32]. The ICC for the steatosis assessments made by the four patholo-
gists on the 46 biopsies was 0.57 [32]. The ICC for steatosis assessments made by the three
hepatopathologists on 59 biopsies in this study was 0.79 (95% CI 0.68–0.87) with a repeatability
coefficient of 38 (95% CI 35–40) % steatosis. By contrast, the ICC determined from the current
Fig 6. Comparison of volumetric liver fat fractionmeasured by HepaFat-Scan1 and stereology. (a)
Volumetric liver fat fraction measured by HepaFat-Scan1 versus the volumetric liver fat fraction measured by
stereology from histology sections of liver biopsy samples. The solid line is the line of equivalence (not a line
of best fit). (b) Bland Altman plot showing the differences of the volumetric liver fat fractions measured by
HepaFat-Scan1 and by stereological analysis of liver biopsy histology sections plotted against mean of the
two measurements. The solid line indicates the mean difference while the dashed lines indicate the upper
and lower 95% limits of agreement between the two measurements.
doi:10.1371/journal.pone.0160789.g006
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study using stereological measurement on 59 biopsies by three analysts was 0.86 (95% CI 0.68–
0.93) with a repeatability coefficient of 8.2 (95% CI 7.7–8.8) % volumetric fat fraction. The
results from this study demonstrate that stereological measurement of volumetric liver fat frac-
tion in biopsies is a method of quantifying hepatic steatosis with a conformity that is superior
to previously published studies on the performance of histopathological grading by visual
assessment and a repeatability coefficient superior to that observed for the three hepatopathol-
ogists in the current study. The good repeatability of the stereological method together with the
minimal bias associated with the principles of stereology indicate that this method could be
Table 2. Receiver operating characteristic curve analysis. Receiver operating characteristic curve analysis of stereology (3 analysts) and HepaFat-Scan
(3 analysts) for prediction of hepatopathologists’ steatosis gradings in biopsies.
Grade 0 vs Grades 1–3 Grades 0&1 vs Grades 2&3 Grades 0–2 vs Grade 3
Stereology
Stereology Cut Point (%)
Pathologist AC > 4.54 > 6.90 > 12.8
Pathologist BD > 5.20 > 11.8 > 16.9
Pathologist PB > 6.48 > 7.64 > 12.8
AUROC (+/- SE)
Pathologist AC 0.941 (0.033) 0.981 (0.013) 0.978 (0.019)
Pathologist BD 0.984 (0.013) 0.968 (0.020) 0.986 (0.016)
Pathologist PB 0.950 (0.028) 0.981 (0.014) 0.969 (0.021)
Sensitivity (%) (95% conf int)
Pathologist AC 88.6 (73.3% to 96.8%) 100.0 (85.8% to 100.0%) 92.9 (66.1% to 99.8%)
Pathologist BD 100.0 (87.7% to 100.0%) 93.3 (68.1% to 99.8%) 100.0 (39.8% to 100.0%)
Pathologist PB 84.9 (68.1% to 94.9%) 100.0 (83.9% to 100.0%) 81.3 (54.4% to 96.0%)
Specificity (%) (95% conf int)
Pathologist AC 95.8 (78.9% to 99.9%) 88.6 (73.3% to 96.8%) 95.6 (84.9% to 99.5%)
Pathologist BD 90.3 (74.2% to 98.0%) 93.2 (81.3% to 98.6%) 94.6 (84.9% to 98.9%)
Pathologist PB 96.2 (80.4% to 99.9%) 91.4 (76.9% to 98.2%) 100.0 (91.2% to 100.0%)
HepaFat-Scan
HepaFat-Scan Cut Point (%)
Pathologist AC > 3.55 > 10.40 > 15.45
Pathologist BD > 5.30 > 15.45 > 20.70
Pathologist PB > 3.55 > 10.40 > 12.55
AUROC (+/- SE)
Pathologist AC 0.945 (0.031) 0.982 (0.013) 0.982 (0.014)
Pathologist BD 0.988 (0.012) 0.967 (0.023) 0.968 (0.023)
Pathologist PB 0.960 (0.033) 0.996 (0.005) 0.977 (0.016)
Sensitivity (%) (95% conf int)
Pathologist AC 91.4 (76.9% to 98.2%) 91.7 (73.0% to 99.0%) 92.9 (66.1% to 99.8%)
Pathologist BD 100.0 (75.3% to 100.0%) 93.3 (68.1% to 99.8%) 100.0 (39.8% to 100.0%)
Pathologist PB 96.7 (82.8% to 99.9%) 100.0 (83.9% to 100.0%) 100.0 (79.4% to 100.0%)
Specificity (%) (95% conf int)
Pathologist AC 91.4 (78.9% to 99.9%) 97.1 (85.1% to 99.9%) 93.3 (81.7% to 98.6%)
Pathologist BD 93.6 (78.6% to 99.2%) 95.5 (84.5% to 99.4%) 94.6 (84.9% to 98.9%)
Pathologist PB 92.3 (74.9% to 99.1%) 97.1 (85.1% to 99.9%) 90.0 (76.3% to 97.2%)
AUROC: Area under receiver operating characteristic curve
doi:10.1371/journal.pone.0160789.t002
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considered as a new reference standard against which new technologies for measurement of
liver fat fraction could be compared.
The patient population in the study had a wide range of hepatic steatosis and represents the
full range of liver conditions encountered in hepatology clinics. All stages of liver fibrosis are
represented in the patient cohort and no confounding effect of fibrosis on the volumetric liver
fat fraction measurements could be detected. No confounding effects of LIC were detected
either, most likely because the HepaFat-Scan1 technique accounts for T2 decay. However,
only low to moderate iron loadings are represented in this study population (maximum LIC
encountered was 4.4 mg Fe/g dw). High LIC has the potential to degrade accuracy of MR mea-
surements of liver fat. Administration of T1 contrast agents such as gadolinium during imaging
would also confound the measurement of fat fraction measured by HepaFat-Scan owing to the
change in T1 of the non-fatty liver tissue.
The inter-analyst repeatability for the stereological measurements of volumetric liver fat
fraction in the biopsy sections, although not as good as the repeatability observed for the Hepa-
Fat-Scan1 measurements, was still much better than that found for the three hepatopatholo-
gists in this study and the reported reproducibility of percentage steatosis by histopathologists
in previous studies (compare Fig 3 in this report with Fig 1 in reference [32], for example).
While significant biases were observed between some pairs of analysts using the stereological
method, they were sufficiently small ( 3.4% volumetric fat fraction) compared with variations
between the hepatopathologists ( 13.9% steatosis) to suggest that stereological analysis of
liver biopsy sections is a better reference standard for measurement of fat fraction than hepato-
pathologists’ assessments (compare Figs 3 and 5).
The inter-analyst repeatability coefficient for measurement of volumetric liver fat fractions
using HepaFat-Scan1 were significantly better than those for the stereological measurements
(compare Figs 3 with 4) with no significant bias observable between the three analysts.
The upper and lower 95% limits of agreement between the measurements made by Hepa-
Fat-Scan1 and the stereological measurements on biopsy sections are determined both by the
random errors on HepaFat-Scan1 and the random errors on the stereology measurements.
While, in principle, stereological point counting analysis yields unbiased results [33], the preci-
sion of stereological analysis depends on the number of intersections examined. For a given
volumetric fat fraction, f, precision improves with the square root of the number, n, of intersec-
tions examined [40]. Hence the choice of mesh size of the square grid (which determines the
number of intersections to be examined) is a compromise between precision and the amount
of analyst time require to complete examination of all intersections. With 200 intersections per
biopsy, we found the time for completing all 200 intersection observations was approximately
3 hours per biopsy. Given the time required to accurately perform the stereology, it is unlikely
such a technique would be suitable for routine clinical analysis.
The bias of 1.4 ± 0.5% volumetric fat fraction between the measurements made by HepaFat-
Scan1 and the stereological measurements on biopsy sections is unlikely to be clinically signifi-
cant. The magnitude of the bias is less than 5% of the overall range of volumetric liver fat frac-
tions encountered in the population. Furthermore, having been measured, the bias can be
taken into account when comparing other measurement techniques that might be compared
against the stereologically measured reference standard in the future.
The areas under the ROC curves and sensitivities and specificities for prediction of the
hepatopathologists’ steatosis grade assessments (Table 2) are also determined to an appreciable
extent by the precision of the hepatopathologists. Nevertheless, the areas under the ROC curves
and sensitivities and specificities indicate that both HepaFat-Scan1 and stereology could be
used for grading steatosis. However, the cut points shown in Table 2 are specific to each
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hepatopathologist because of the biases that can occur between hepatopathologists as also
shown by El-Badry et al [32].
A limitation of the current study is that only one form of histological staining was assessed
(Masson’s trichrome). It is possible that different stains could affect the degree of bias mea-
sured. With the paraffin embedded Masson trichrome stained sections used in this study, lipid
fat vesicles appear as holes or, if smaller than the thickness of the section, lower contrast vesi-
cles. Other stains such as Oil Red can be used to directly stain lipid droplets on sections of fro-
zen tissue [39] enabling computer assisted measurement of lipid vesicles using coloured pixel
counting. While lipid staining techniques have a clear advantage over trichrome stained meth-
ods when using computer assisted pixel colour measurement, for point counting stereological
techniques, where human observation is directed to a discrete number of exact points in an
image for categorization, the advantage of lipid staining is less clear. For example, in the study
by Catta-Preta and colleagues [39] comparing different staining techniques with a stereological
point counting method for quantifying hepatic steatosis in mouse livers, hematoxylin and
eosin (H&E) staining was found to give significantly better inter-observer reproducibility than
Oil Red stained sections. Coefficients of variation of results from three analysts were found to
be 4.0 and 27.3% (for mice on standard chow) and 1.2 and 7.5% (for mice on high fat chow)
for H&E stained and Oil Red stained sections respectively.
In summary, the data presented here suggest that stereological analysis of liver biopsy sec-
tions using the point counting method together with the Delesse principle provides a good ref-
erence standard against which non-invasive methods of measurement of liver fat fraction can
be compared or validated. In the case of this study, the MRI technique HepaFat-Scan1 has
been shown to have minimal bias in the measurement of volumetric liver fat fraction when
compared with biopsy measurements using stereology.
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